Fractyl's Revita cuts weight regain after GLP-1 stop in REMAIN-1 trial
Fractyl Health said its one-time Revita procedure helped patients keep about 80% of weight lost on a GLP-1 drug six months after stopping, versus 67% with a sham procedure.
Fractyl Health reported that its Revita procedure reduced weight regain after people stopped taking a GLP-1 obesity drug, meeting the first of two main goals in a 308-person randomized, sham-controlled trial called REMAIN-1 [1]. The company said it plans to file a De Novo marketing application with the FDA in late Q4 2026 [1].
In the modified intention-to-treat population of 308 people, those treated with a single Revita procedure kept about 80% of the weight loss they had achieved on medication, compared with 67% of those who received a sham endoscopic procedure, according to the company [1]. Average weight regain was 5.1% of body weight with Revita versus 8.2% with sham, a difference the company reported as statistically significant (p=0.0023) [1]. That comparison covered 176 Revita participants and 74 sham participants [1]. Separately, 32% of Revita participants were either weight-stable or still losing weight six months after stopping the drug, defined as less than 2% regain, versus 18% of sham participants; the company labeled that finding post hoc with a nominal p=0.020 [1].
A post hoc analysis by how much of the duodenum was ablated found a larger effect with longer treatment [1]. Participants who received 12 to 18 centimeters of duodenal ablation regained 4.7% of body weight versus 8.2% with sham, which the company described as 43% less regain, based on 107 Revita participants and 74 sham participants [1]. Those who received 20 centimeters or more regained 3.8%, described as 53% less regain, based on 47 participants; the company measured this change between Month 1 and Month 6 [1]. Fractyl said the gap in weight regain between Revita and sham nearly doubled between Month 3 and Month 6 [1].
On safety, Fractyl reported no device- or procedure-related serious adverse events, no deaths, and no unanticipated adverse device effects as of a September 24, 2026 data cutoff [1]. Related adverse events were mostly mild and clustered around the procedure, with 94% occurring within seven days and the vast majority within two days, the company said [1].
REMAIN-1 enrolled adults with obesity and a body mass index of 30 to 45 who did not have type 2 diabetes and had not previously taken a GLP-1 drug, at more than 30 U.S. sites [1]. Participants first took tirzepatide until they lost at least 15% of body weight, then stopped the drug and were randomly assigned 2:1 to one Revita procedure or a sham endoscopy [1]. Revita is a one-time endoscopic procedure intended to remodel the lining of the duodenum; it holds FDA Breakthrough Device designation for weight maintenance after GLP-1 discontinuation and is for investigational use only in the United States, though it is CE marked in the European Union and United Kingdom [1].
Why it matters for patients
Regaining weight after stopping a GLP-1 drug is a common concern, and there is currently no approved procedure in the United States aimed at preventing it [1]. Adrian Dan, M.D., medical director of the Weight Management Institute at Summa Health, said in the announcement that patients who do well on a GLP-1 often ask "Do I have to stay on this forever?" [1].
Several limits are worth knowing. The headline result covers six months; whether the effect holds at one year has not been reported [1]. The length-of-ablation findings came from post hoc analyses, meaning they were not pre-planned comparisons, and the group receiving 20 centimeters or more numbered 47 [1]. Everyone in this cohort lost at least 15% of body weight on tirzepatide before the procedure, so results in people who lost less, or who took semaglutide, have not been reported. The company has not disclosed what the procedure would cost or how insurers would cover it [1].
What happens next
- Late Q4 2026: Fractyl plans to submit a De Novo marketing application to the FDA for weight maintenance after GLP-1 therapy [1].
- January 1, 2027: A Category III CPT code, 1122T, takes effect for the Revita procedure [1].
- Q1 2027: Topline one-year data from the pivotal cohort are expected, including the second co-primary endpoint — the share of participants keeping at least 5% weight loss, measured against an FDA-set performance goal of greater than 50% [1].
- Late 2027: Potential FDA marketing authorization [1].
- Early 2028: Potential U.S. commercial launch [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.